Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Tuberculosis

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    March 2018
  1. CANEZIN PH, Caleffi-Ferracioli KR, Scodro RBL, Siqueira VLD, et al
    Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
    J Antimicrob Chemother. 2018 Mar 22. pii: 4951545. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  2. DOOKIE N, Rambaran S, Padayatchi N, Mahomed S, et al
    Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.
    J Antimicrob Chemother. 2018 Jan 19. pii: 4817621. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  3. LIU Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, et al
    Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    J Antimicrob Chemother. 2017 Dec 12. pii: 4735127. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  4. VYAZOVAYA A, Levina K, Zhuravlev V, Viiklepp P, et al
    Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context.
    J Antimicrob Chemother. 2017 Oct 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. YEW WW, Liang D, Chan DP, Shi W, et al
    Molecular mechanisms of clofazimine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017;72:2943-2944.
    PubMed     Text format    


    September 2017
  6. CHEN J, Zhang S, Cui P, Shi W, et al
    Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Sep 12. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  7. SVENSSON RJ, Gillespie SH, Simonsson USH
    Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.
    J Antimicrob Chemother. 2017;72:2311-2319.
    PubMed     Text format     Abstract available


    June 2017
  8. KAUSHIK A, Ammerman NC, Tasneen R, Story-Roller E, et al
    In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. YEW WW, Leung CC, Zhang Y
    Oxidative stress and TB outcomes in patients with diabetes mellitus?
    J Antimicrob Chemother. 2017;72:1552-1555.
    PubMed     Text format     Abstract available


    May 2017
  10. MAITRE T, Petitjean G, Chauffour A, Bernard C, et al
    Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
    J Antimicrob Chemother. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. NAIDOO A, Chirehwa M, McIlleron H, Naidoo K, et al
    Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    J Antimicrob Chemother. 2017;72:1441-1449.
    PubMed     Text format     Abstract available


    April 2017
  12. ZIMENKOV DV, Nosova EY, Kulagina EV, Antonova OV, et al
    Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    J Antimicrob Chemother. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. SEKAGGYA-WILTSHIRE C, von Braun A, Scherrer AU, Manabe YC, et al
    Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
    J Antimicrob Chemother. 2017;72:1172-1177.
    PubMed     Text format     Abstract available


    March 2017
  14. GURUMURTHY M, Verma R, Naftalin CM, Hee KH, et al
    Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    J Antimicrob Chemother. 2017 Mar 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. JAGANATH D, Schaaf HS, Donald PR
    Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
    J Antimicrob Chemother. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. VILLELLAS C, Coeck N, Meehan CJ, Lounis N, et al
    Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    J Antimicrob Chemother. 2017;72:684-690.
    PubMed     Text format     Abstract available


    February 2017
  17. CAVANAUGH JS, Jou R, Wu MH, Dalton T, et al
    Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. CHOLO MC, Mothiba MT, Fourie B, Anderson R, et al
    Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.
    J Antimicrob Chemother. 2017;72:338-353.
    PubMed     Text format     Abstract available


    January 2017
  19. GOTHAM D, Fortunak J, Pozniak A, Khoo S, et al
    Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw522. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  20. ROBERTSON GT, Scherman MS, Bruhn DF, Liu J, et al
    Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw467. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. NAGU TJ, Aboud S, Matee MI, Maeurer MJ, et al
    Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw503. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  22. AMMERMAN NC, Swanson RV, Tapley A, Moodley C, et al
    Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    September 2016
  23. HOFFMANN H, Borroni E, Schena E, Nedialkova L, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system-authors' response.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  24. BERNARD C, Aubry A, Chauffour A, Brossier F, et al
    In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    August 2016
  25. IMKAMP F, Keller PM, Bottger EC
    Comment on: Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


    June 2016
  26. EILERTSON B, Maruri F, Blackman A, Guo Y, et al
    A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  27. DUTTA NK, Bruiners N, Pinn ML, Zimmerman MD, et al
    Statin adjunctive therapy shortens the duration of TB treatment in mice.
    J Antimicrob Chemother. 2016;71:1570-7.
    PubMed     Text format     Abstract available


    May 2016
  28. PANTEL A, Petrella S, Veziris N, Matrat S, et al
    Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  29. HENNIG S, Svensson EM, Niebecker R, Fourie PB, et al
    Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
    J Antimicrob Chemother. 2016;71:1330-40.
    PubMed     Text format     Abstract available


  30. COJUTTI P, Duranti S, Isola M, Baraldo M, et al
    Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
    J Antimicrob Chemother. 2016;71:1323-9.
    PubMed     Text format     Abstract available


    April 2016
  31. SCHENA E, Nedialkova L, Borroni E, Battaglia S, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  32. PANDIE M, Wiesner L, McIlleron H, Hughes J, et al
    Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    J Antimicrob Chemother. 2016;71:1037-40.
    PubMed     Text format     Abstract available


  33. OLARU ID, Lange C, Heyckendorf J
    Personalized medicine for patients with MDR-TB.
    J Antimicrob Chemother. 2016;71:852-5.
    PubMed     Text format     Abstract available


    March 2016
  34. SAKTIAWATI AM, Sturkenboom MG, Stienstra Y, Subronto YW, et al
    Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    J Antimicrob Chemother. 2016;71:703-10.
    PubMed     Text format     Abstract available


  35. RIEU R, Chang C, Collin SM, Fazekas J, et al
    Time to detection in liquid culture of sputum in pulmonary MDR-TB does not predict culture conversion for early discharge.
    J Antimicrob Chemother. 2016;71:803-6.
    PubMed     Text format     Abstract available


    February 2016
  36. ZIMENKOV DV, Kulagina EV, Antonova OV, Zhuravlev VY, et al
    Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  37. COECK N, de Jong BC, Diels M, de Rijk P, et al
    Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  38. RIGOUTS L, Coeck N, Gumusboga M, de Rijk WB, et al
    Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
    J Antimicrob Chemother. 2016;71:314-23.
    PubMed     Text format     Abstract available


    December 2015
  39. CLEWE O, Aulin L, Hu Y, Coates AR, et al
    A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  40. LOOTS DT
    New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  41. LORTHOLARY O, Roussillon C, Boucherie C, Padoin C, et al
    Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    November 2015
  42. NIWARD K, Angeby K, Chryssanthou E, Paues J, et al
    Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  43. MEFTAHI N, Namouchi A, Mhenni B, Brandis G, et al
    Evidence for the critical role of a secondary site rpoB mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    August 2015
  44. JAGIELSKI T, Bakula Z, Roeske K, Kaminski M, et al
    Mutation profiling for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  45. KNUDSON SE, Awasthi D, Kumar K, Carreau A, et al
    Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    July 2015
  46. JEONG BH, Jeon K, Park HY, Kwon OJ, et al
    Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  47. BAX HI, de Steenwinkel JE, Ten Kate MT, van der Meijden A, et al
    Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    June 2015
  48. ZHANG S, Chen J, Cui P, Shi W, et al
    Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    May 2015
  49. TORREA G, Coeck N, Desmaretz C, Van De Parre T, et al
    Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  50. MARTINEZ E, Holmes N, Jelfs P, Sintchenko V, et al
    Genome sequencing reveals novel deletions associated with secondary resistance to pyrazinamide in MDR Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


  51. HEINRICH N, Dawson R, du Bois J, Narunsky K, et al
    Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
    J Antimicrob Chemother. 2015;70:1558-66.
    PubMed     Text format     Abstract available


  52. KIM SH, Lee SO, Park IA, Kim SM, et al
    Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-gamma-releasing assay: an exploratory randomized controlled trial.
    J Antimicrob Chemother. 2015;70:1567-72.
    PubMed     Text format     Abstract available


    April 2015
  53. HIRUY H, Rogers Z, Mbowane C, Adamson J, et al
    Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.
    J Antimicrob Chemother. 2015;70:1115-23.
    PubMed     Text format     Abstract available


  54. OUTHRED AC, Jelfs P, Suliman B, Hill-Cawthorne GA, et al
    Added value of whole-genome sequencing for management of highly drug-resistant TB.
    J Antimicrob Chemother. 2015;70:1198-202.
    PubMed     Text format     Abstract available


    March 2015
  55. CAMBAU E, Viveiros M, Machado D, Raskine L, et al
    Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.
    J Antimicrob Chemother. 2015;70:686-96.
    PubMed     Text format     Abstract available


    February 2015
  56. MOULTRIE H, McIlleron H, Sawry S, Kellermann T, et al
    Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
    J Antimicrob Chemother. 2015;70:543-9.
    PubMed     Text format     Abstract available


  57. HUANG Z, Qin C, Du J, Luo Q, et al
    Evaluation of the microscopic observation drug susceptibility assay for the rapid detection of MDR-TB and XDR-TB in China: a prospective multicentre study.
    J Antimicrob Chemother. 2015;70:456-62.
    PubMed     Text format     Abstract available


  58. REYNOLDS HE, Chrdle A, Egan D, Chaponda M, et al
    Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.
    J Antimicrob Chemother. 2015;70:550-4.
    PubMed     Text format     Abstract available


    April 2014
  59. KALITA J, Misra UK, Prasad S, Bhoi SK, et al
    Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial.
    J Antimicrob Chemother. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: